Allergen Immunotherapy in Asthma

Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kazuyuki Nakagome, Makoto Nagata
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	allergen immunotherapy bronchial asthma subcutaneous immunotherapy sublingual immunotherapy Medicine R
Acceso en línea:	https://doaj.org/article/5d99a033e29844ca85c182e9c2f67498
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d99a033e29844ca85c182e9c2f67498
record_format	dspace
spelling	oai:doaj.org-article:5d99a033e29844ca85c182e9c2f674982021-11-25T18:38:00ZAllergen Immunotherapy in Asthma10.3390/pathogens101114062076-0817https://doaj.org/article/5d99a033e29844ca85c182e9c2f674982021-10-01T00:00:00Zhttps://www.mdpi.com/2076-0817/10/11/1406https://doaj.org/toc/2076-0817Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and decreases airway hyper responsiveness and medication dose. In addition, AIT can improve the natural course of asthma. For example, the effects of AIT can be preserved for at least a few years, even after ending treatment. AIT may increase the remission rate of asthma in children and suppress sensitization to new allergens. If AIT is introduced in pollinosis, AIT may prevent the development of asthma. Moreover, AIT can control other allergic diseases complicated by asthma, such as allergic rhinitis, which also improves the control of asthma. The indication of HDM-SCIT for asthma is mild-to-moderate HDM-sensitized allergic asthma in a patient with normal respiratory function. To date, HDM-SLIT is applicable in Japan for allergic rhinitis, not for asthma. However, the effect of SLIT on asthma has been confirmed internationally, and SLIT is available for asthma in Japan if allergic rhinitis is present as a complication.Kazuyuki NakagomeMakoto NagataMDPI AGarticleallergen immunotherapybronchial asthmasubcutaneous immunotherapysublingual immunotherapyMedicineRENPathogens, Vol 10, Iss 1406, p 1406 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	allergen immunotherapy bronchial asthma subcutaneous immunotherapy sublingual immunotherapy Medicine R
spellingShingle	allergen immunotherapy bronchial asthma subcutaneous immunotherapy sublingual immunotherapy Medicine R Kazuyuki Nakagome Makoto Nagata Allergen Immunotherapy in Asthma
description	Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In asthma, AIT using the house dust mite (HDM) alleviates clinical symptoms and decreases airway hyper responsiveness and medication dose. In addition, AIT can improve the natural course of asthma. For example, the effects of AIT can be preserved for at least a few years, even after ending treatment. AIT may increase the remission rate of asthma in children and suppress sensitization to new allergens. If AIT is introduced in pollinosis, AIT may prevent the development of asthma. Moreover, AIT can control other allergic diseases complicated by asthma, such as allergic rhinitis, which also improves the control of asthma. The indication of HDM-SCIT for asthma is mild-to-moderate HDM-sensitized allergic asthma in a patient with normal respiratory function. To date, HDM-SLIT is applicable in Japan for allergic rhinitis, not for asthma. However, the effect of SLIT on asthma has been confirmed internationally, and SLIT is available for asthma in Japan if allergic rhinitis is present as a complication.
format	article
author	Kazuyuki Nakagome Makoto Nagata
author_facet	Kazuyuki Nakagome Makoto Nagata
author_sort	Kazuyuki Nakagome
title	Allergen Immunotherapy in Asthma
title_short	Allergen Immunotherapy in Asthma
title_full	Allergen Immunotherapy in Asthma
title_fullStr	Allergen Immunotherapy in Asthma
title_full_unstemmed	Allergen Immunotherapy in Asthma
title_sort	allergen immunotherapy in asthma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5d99a033e29844ca85c182e9c2f67498
work_keys_str_mv	AT kazuyukinakagome allergenimmunotherapyinasthma AT makotonagata allergenimmunotherapyinasthma
_version_	1718410893004374016

Allergen Immunotherapy in Asthma

Ejemplares similares